Stocks of Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) traded higher last session on Wall Street, down -0.86% to $10.33.
According to the data, Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) has 13 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $18.00 and a low of $8.00, we find $12.00. Given the previous closing price of $10.42, this indicates a potential upside of 15.16 percent. MRVI stock price is now -11.57% away from the 50-day moving average and -23.28% away from the 200-day moving average. The market capitalization of the company currently stands at $2.52B.
A total of 5 analysts have issued a hold rating and 7 have given it a buy rating. Brokers who have rated the stock have averaged $13.34 as their price target over the next twelve months.
Insiders disposed of 24,488 shares of company stock worth roughly $0.25 million over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in MRVI stock. A new stake in Maravai LifeSciences Holdings Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $18,643,000. AMERIPRISE FINANCIAL INC invested $17,303,000 in shares of MRVI during the first quarter. In the first quarter, RTW INVESTMENTS, LP acquired a new stake in Maravai LifeSciences Holdings Inc. valued at approximately $15,833,000. BALYASNY ASSET MANAGEMENT L.P. acquired a new stake in MRVI for approximately $7,016,000. KORNITZER CAPITAL MANAGEMENT INC /KS purchased a new stake in MRVI valued at around $5,332,000 in the second quarter.
During the past 12 months, Maravai LifeSciences Holdings Inc. has had a low of $9.20 and a high of $26.55. As of last week, the company has a debt-to-equity ratio of 1.07, a current ratio of 9.30, and a quick ratio of 8.70. The fifty day moving average price for MRVI is $11.63 and a two-hundred day moving average price translates $13.44 for the stock.
The latest earnings results from Maravai LifeSciences Holdings Inc. (NASDAQ: MRVI) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at $0, missing analysts’ expectations of $0.01 by -0.01. This compares to $0.61 EPS in the same period last year. The net profit margin was 13.90% and return on equity was 14.40% for MRVI. The company reported revenue of $68.91 million for the quarter, compared to $242.73 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -71.61 percent. For the current quarter, analysts expect MRVI to generate $75.63M in revenue.
Maravai LifeSciences Holdings Inc.(MRVI) Company Profile
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
